I never lose. I either win or learn.
–Nelson Mandela
Gilead Sciences (GILD) is a multibillion ($89B market cap) biopharmaceutical company that has and is still revolutionizing the infectious disease market with innovative anti-viral therapies for HIV/AIDS, Hep B and C. It seems that the market wasn’t impressed with the recent Q1 earnings report, an issue that has been addressed by many recent articles on this SA platform. With stock price depreciation and lackluster earnings report it seems some folks are losing their marbles with Gilead. A quote from Nelson Mandela comes to mind